Table 1.
Clinical Characteristics, Concomitant Diseases, and Treatment at Baseline
| Demographics | |
|---|---|
| No. of Patients | 25 |
| Age, y | 63.8 ± 6.9 |
| Male/Female, % | 68/32 |
| Weight, kg | 75.9 ± 16.8 |
| NYHA class, II/III, % | 44/56 |
| LV ejection Fraction, % | 30.0 ± 8.0 |
| Concomitant diseases | |
| Diabetes mellitus, % | 40 |
| Hypertension, % | 80 |
| Dislipidemia, % | 28 |
| Ischemic heart disease, % | 44 |
| Etiology | |
| Idiopathic, % | 24 |
| Ischemic, % | 32 |
| Hypertensive, % | 20 |
| Postmyocarditis, % | 4 |
| Other, % | 20 |
| Treatment at inclusion | |
| Furosemide, %, mg/d | 92, 80 |
| Metolazone, % | 16 |
| Spironolactone, % | 56 |
| ACE inhibitor, % | 80 |
| Angiotensin receptor blocker, % | 24 |
| β‐blocker, % | 88 |
| 50% β‐blocker target dose, % | 45 |
| Digoxin, % | 24 |
| Statins, % | 56 |
| CRT, % | 28 |
Abbreviations: ACE, angiotensin‐converting enzyme; CRT, cardiac resynchronization therapy; LV, left ventricular, NYHA, New York Heart Association.